Inactive Instrument

Press Releases US Rare Earth Minerals Inc Other OTC

Equities

US9034101082

End-of-day quote Other OTC Other stock markets
- ^USD	-

19/04	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
19/04	Bioxytran, Inc. Announces Board Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bioxytran : Change in Certifying Accountants - Form 8-K	10/05	PU
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist	06/03	AQ
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19	21/02	AQ
Bioxytran Gets Broad Patent Coverage on 60+ Viruses	24/23/24	AQ
Bioxytran Interview at the Emerging Growth Conference	04/23/04	AQ
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M	14/23/14	AQ
Bioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patients	07/23/07	AQ
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials	31/23/31	AQ
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials	24/23/24	AQ
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients	08/23/08	AQ
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board	31/23/31	AQ
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations	27/23/27	AQ
Bioxytran Expands Institutional Investor Base with an additional $500,000 Equity Investment	12/23/12	AQ
Bioxytran Interview at the Emerging Growth Conference	01/23/01	AQ
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials	19/23/19	AQ
Bioxytran Interview at the Emerging Growth Conference	04/23/04	AQ
BIOXYTRAN, INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	01/23/01	AQ
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal	29/23/29	AQ
BIOXYTRAN, INC : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	08/23/08	AQ
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus	28/23/28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases US Rare Earth Minerals Inc Other OTC

Equities

US9034101082

Press Releases

Filters